Yuflyma

ADALIMUMAB

Manufacturer: CELLTRION USA, Inc.

Score: 144.0

Quick Summary

Yuflyma (adalimumab) is a tumor necrosis factor (TNF) blocker used to treat various conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. The drug works by binding to TNF-alpha and blocking its interaction with cell surface receptors, which helps reduce inflammation and modulate the immune system. Important safety information includes the risk of serious infections, malignancies, and adverse reactions such as injection site reactions and allergic reactions. The recommended dosage varies depending on the condition being treated, with initial dosing and titration schedules provided for adults and pediatric patients. Special population considerations include use during pregnancy, nursing mothers, pediatric use, and geriatric use, with specific guidance provided for each group.

Key Clinical Findings and Indications

Rheumatoid arthritis
Juvenile idiopathic arthritis
Psoriatic arthritis
Ankylosing spondylitis
Crohn's disease
Ulcerative colitis
Plaque psoriasis
Hidradenitis suppurativa
Uveitis

Important Safety Information

Warning

Increased risk of serious infections and malignancies

Contraindications

Adverse Reactions

Injection site reactions
Allergic reactions
Serious infections
Malignancies

Dosing Recommendations

General Guidance

Dose adjustments may be necessary based on patient response and tolerability

Rheumatoid arthritis

Adult Dose

40 mg every other week

Pediatric Dose

20 mg every other week for patients 15 kg to less than 30 kg, 40 mg every other week for patients 30 kg and greater

Crohn's disease

Adult Dose

160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29

Pediatric Dose

17 kg to less than 40 kg: 80 mg on Day 1, 40 mg on Day 15, and 20 mg every other week starting on Day 29; 40 kg and greater: 160 mg on Day 1, 80 mg on Day 15, and 40 mg every other week starting on Day 29

Special Population Considerations

Pregnancy

Use during pregnancy only if potential benefits justify potential risks

Nursing Mothers

Caution advised when administering to nursing mothers

Pediatric Use

Approved for use in pediatric patients 2 years of age and older with juvenile idiopathic arthritis
Approved for use in pediatric patients 6 years of age and older with Crohn's disease